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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that mediate post-transcriptional gene silencing. Over 700 human miRNAs
have currently been identified, many of which are mutated or de-regulated in diseases. Here we report the identification of
novel miRNAs through deep sequencing the small RNAome (,30 nt) of over 100 tissues or cell lines derived from human
female reproductive organs in both normal and disease states. These specimens include ovarian epithelium and ovarian
cancer, endometrium and endometriomas, and uterine myometrium and uterine smooth muscle tumors. Sequence reads
not aligning with known miRNAs were each mapped to the genome to extract flanking sequences. These extended
sequence regions were folded in silico to identify RNA hairpins. Sequences demonstrating the ability to form a stem loop
structure with low minimum free energy (,225 kcal) and predicted Drosha and Dicer cut sites yielding a mature miRNA
sequence matching the actual sequence were considered putative novel miRNAs. Additional confidence was achieved when
putative novel hairpins assembled a collection of sequences highly similar to the putative mature miRNA but with
heterogeneous 39-ends. A confirmed novel miRNA fulfilled these criteria and had its ‘‘star’’ sequence in our collection. We
found 7 distinct confirmed novel miRNAs, and 51 additional novel miRNAs that represented highly confident predictions
but without detectable star sequences. Our novel miRNAs were detectable in multiple samples, but expressed at low levels
and not specific to any one tissue or cell type. To date, this study represents the largest set of samples analyzed together to
identify novel miRNAs.
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Introduction
MicroRNAs (miRNAs) are short (,22-nucleotide), single-
stranded, non-coding RNAs that modulate gene expression.
Through their binding to the 39-UTR (untranslated region) of
target mRNAs, miRNAs trigger either the degradation of the
mRNA transcript or the inhibition of protein translation. miRNAs
are initially transcribed as primary microRNAs (pri-miRNAs) and
then undergo two processing steps. The first step is the generation,
within the nucleus, of stem-loop precursors (pre-miRNAs ,70 nt)
by the enzyme Drosha. In the second step, the pre-miRNAs are
exported into the cytoplasm and processed by the enzyme Dicer
into a double stranded RNA duplex with two nucleotide 39-
overhangs, subsequently releasing the 17–25 nucleotide long
mature miRNA. miRNAs are essential for normal mammalian
development and help regulate genes and processes involved in
cell growth, differentiation, and apoptosis [1]. Alterations in
miRNA expression have been observed in a variety of human
cancers [2,3,4] including ovarian cancer [5,6,7]. miRNAs also
appear deregulated in other diseases affecting organs of the
reproductive system such as uterine leiomyomas and endometri-
osis [8,9,10].
The number of miRNAs confidently identified in the human
genome is currently over 700 (703 in miRBase v13.0). Though the
actual number of miRNAs is not known, some in silico studies
suggest as many as tens of thousands of miRNAs exist [11].
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approaches such as cloning and Sanger sequencing [12]. However,
the recent introduction of deep sequencing technology, enabling
the simultaneous sequencing of up to millions of DNA or RNA
molecules, has provided another option for the discovery of novel
miRNAs that may have eluded previous efforts [13]. Previous
studies using computational methods combined with high
throughput experimental data—such as deep sequencing or tiling
expression arrays—have successfully identified novel miRNAs
[14,15,16,17].
To date, we have exhaustively sequenced the small RNAome of
over 100 human samples derived from various organs of the
female reproductive system in both diseased and normal states,
including ovarian samples (both normal epithelium and ovarian
cancer), endometrial samples (from both healthy non-endometri-
osis and endometriosis patients), and uterine samples (both
normal myometrium and benign and malignant uterine tumors).
Studies on the functional roles of known miRNAs in the diseased
states of these various systems are currently ongoing and either
have been [18,19] or will be described in other papers. However,
the exceptional volume of sequence data generated from this work
provided us a unique opportunity to mine for novel miRNAs that
have eluded previous cloning and standard sequencing efforts. In
the present study, we focused on novel miRNA discovery and
have confidently identified both mature and star sequences for 7
previously unknown miRNAs using our deep sequencing data.
We have also identified nearly 100 additional putative novel
miRNAs with mid-to-high confidence which await additional
confirmation.
Results
Using Next Generation Sequencing, we dissected the small
RNAome of 103 human specimens obtained or derived from
various tissues from female reproductive system-related organs.
Samples profiled are listed in Table 1. These specimens included
short-term cultures of normal ovarian surface epithelium (NOSE),
primary ovarian cancers and established cell lines (including
serous, clear cell, and endometrioid histotypes), endometrium from
normal and endometriosis patients, cyst wall from endometriomas,
and uterine myometrium and uterine smooth muscle tumors
(leiomyomas and leiomyosarcomas subtypes). Our sequencing
efforts uncovered a large number of small RNA sequences that
were unlike any known human miRNAs. We hypothesized that
some of these unique sequences were novel human miRNAs and
further examined them using a computational method for miRNA
discovery that was developed by our group to integrate several
published criteria for miRNA prediction [13,20,21].
A schematic for our sequence analysis workflow is shown in
Figure 1. In all, there were over 300 million valid sequence reads
obtained from the 103 samples (‘‘valid’’ sequence reads passing
our quality control filters described in Methods), of which about
216 million mapped to known mature miRNAs, and an additional
15.6 million mapped to a known miRNA hairpin sequence (these
sequences presumably representing the byproducts of miRNA
processing). The remaining ,69 million sequence reads not
aligning with a known miRNA precursor (representing potential
novel miRNAs) were mapped to the entire human genome. Those
reads that mapped exactly to the genome were used to extract
200bp of genomic sequence flanking either side and folded as
RNA using the Vienna RNA secondary structure prediction and
comparison package [22]. The resulting putative novel hairpins
were then filtered for single stem loop hairpins with the putative
mature miRNA read sequence mapping to one side of the stem
and satisfying the Ambros criteria for hairpin structures [20].
Valid novel miRNA hairpins whose putative mature miRNA
sequence was identified in at least one of our samples were
considered to represent putative novel microRNAs. In all, we
identified 14,731 sequence reads representing 132 distinct putative
novel miRNAs by virtue of their ability to form miRNA-like single
hairpins. Here, we used the naming convention ‘‘hsa-bcm-miR-
X’’ for each novel miRNAs, where ‘‘bcm’’ symbolizes ‘‘Baylor
College of Medicine’’ and ‘‘X’’ is a unique identifier. Of the 132
novel miRNA, 20 mapped to multiple genomic loci; in this case,
we used the mirBase convention of ‘‘-1,-2,-3, etc.’’ endings to the
miRNA root name (e.g. ‘‘hsa-bcm-miR-15-1’’, ‘‘hsa-bcm-miR-15-
2’’, and ‘‘hsa-bcm-miR-15-3’’).
In addition to a name referring to the miRNA mature sequence,
each novel miRNA genomic mapping received a unique hairpin
identifier referring to the associated predicted hairpin structure.
We used our putative novel hairpin sequences as precursors for
alignment of all reads that did not map to a known miRNA
precursor. In the next step of our analysis, we screened for putative
novel hairpins that captured a collection of sequences (strong
signal) mapping to a specific region of 15–25 nt within the
reference hairpin on one side of the stem. Scattered sequence
mappings across the full length of hairpin, a strong signal in a
limited region that mapped to the loop, and hairpins mapping to
known tRNA or ribosomal RNA regions were rejected. The strong
signal was expected to contain short 17–25 nt sequences that
exhibited a stable 59-end and significant length heterogeneity at
the 39-end. The sequence with the highest copy number was
considered the putative novel mature miRNA. The other related
sequences were hypothesized to have been generated through
‘imperfect’ Dicer processing events reported by Morin et al. [23]
and Reid et al. [24]. Additionally, predicted Drosha and Dicer cut
sites must have been able to yield a mature miRNA sequence that
matched to the actual miRNA sequence read. If a putative novel
miRNA fulfilled all of the above, we denoted the novel miRNA as
representing a ‘‘high confidence’’ prediction. In all, we identified
5,773 sequence reads representing 58 distinct high confidence, novel
miRNAs.
For confirmation of these high confidence novel miRNAs, we
needed to detect the star sequence in addition to the mature
Table 1. Reproductive tissues profiled.
Description
Number of
samples
(103 total)
Normal ovarian surface epithelium (NOSE), cell culture 4
Primary ovarian cancer, serous, malignant 8
Primary cancer, ovarian, serous, borderline malignant 1
Primary ovarian cancer, endometrioid, malignant 4
Ovarian cancer cell culture, clear cell 12
Ovarian cancer cell culture, serous 4
Endometrioma 10
Endometrium, non-endometriosis 10
Endometrium, endometriosis 3
Uterine leiomyoma 18
Uterine myometrium 18
Uterine leiomyosarcoma 9
Uterine leiomyosarcoma, cell culture 2
doi:10.1371/journal.pone.0009637.t001
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at a much lower frequency since star sequences are degraded and
usually occur at significantly lower levels). We defined the potential
star sequence as the sequence base pairing to the potential mature
sequence on the novel hairpin, correcting for the 2-nt 39 overhangs
which are known to be typical for Dicer processing [14,23]. We
denoted high-confidence novel miRNAs as ‘‘confirmed’’ if the star
sequence was independently detected along with the mature
sequence, as the novel miRNA sequence in question was then
shown to fulfill all of the criteria that could be applied to known
miRNAs. In all, we identified 1334 sequence reads representing
seven distinct confirmed novel miRNAs.
The complete list of confirmed and/or high confidence novel
miRNAs is provided in Table 2. The inability of our sequencing
efforts to discover the star sequence for the 51 high confidence
(but not ‘‘confirmed’’) candidates does not necessarily eliminate
them as representing novel miRNAs. Star sequences (passenger
strands) are usually degraded after Dicer processing of the
hairpin and therefore are present in much lower abundance than
the active miRNA (guide strand). In particular, when the
sequence copy numbers of a mature miRNA are relatively low,
an even lower abundance of the miRNA star form may make it
undetectable. In fact, for many of the low abundance known
miRNAs that we identified (including hsa-miR-1301, hsa-miR-
183, hsa-miR-203, and hsa-miR-371), we were unable to detect
their representative star sequence (data not shown). For the seven
novel miRNAs confirmed by virtue of star sequence identifica-
tion, the predicted secondary structures of the precursor hairpins
are represented in Figure 2. For most of these hairpins (with the
possible exception of the hairpin formed by ‘‘hsa-bcm-miR-8’’),
the small 39 overhangs, which are known to be typical for Dicer
processing, were evident.
We also identified an additional 46 putative novel miRNAs
(representing 2,715 sequence reads) that were flagged as
‘‘potential,’’ pending additional confirmation. These candidates
had weak predicted Dicer and Drosha processing sites in the
predicted hairpin structure, yet at the same time, these structures
did show stable 59 ends and variable 39-ends. One of these
potential candidates (‘‘hsa-bcm-miR-49’’) fulfilled all the criteria
for the candidates at the high confidence level, and also mapped to
a known snRNA. Since snoRNA ACA45 was found to be
processed into a miRNA [25], hsa-bcm-miR-49 might represent
another snRNA that can be processed into a miRNA. The
complete set of confirmed, high confidence, and potential novel
miRNA candidates, as well as the rest of the candidates out of the
original list of 132 putative novel miRNAs that failed our
additional stringency criteria, are provided as Supporting Data
File S1. This file includes the information on the samples in which
each miRNA was identified. The hairpin structure predictions for
each of the 132 putative novel miRNAs is provided as Supporting
Data File S2.
Figure 3A shows the relative abundance levels of both our
confirmed and high confidence novel miRNAs across the samples
profiled. When compared to the set of known miRNAs from our
samples, our novel miRNAs were at much lower abundance levels.
Even the most abundant novel miRNAs were at levels lower than
most of the known miRNAs and several logs lower than what was
observed for the let-7 family. Most of our confirmed and high
confidence novel miRNAs were detected in multiple samples with
various sequence copy numbers (Figure 3B as well as Table 2).
Over 60% of the putative miRNAs were detected in more than a
single sample. The novel miRNAs did not appear to be
preferentially expressed in one reproductive tissue type versus
another (Figure 3B). Many miRNAs were detectable in multiple
reproductive tissue types. Statistically, we were not able to identify
novel miRNAs as being specific to a diseased tissue as compared to
the corresponding normal tissue type. Using an alternative method
from deep sequencing, we were able to confirm expression by
qPCR of one ‘‘high confidence’’ novel hsa-bcm-miR-15
(Figure 3C), which was the seventh most abundant novel miRNA
in our list (and the most abundant miRNA detected in cell lines for
which we had RNA).
Figure 1. Flow chart of the mapping of deep sequence reads to novel miRNAs.
doi:10.1371/journal.pone.0009637.g001
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bcm-miR UCSC Blat Sequence Position (st=strand) Samples detected
Novel microRNAs, confirmed by detection of star sequence
8 Intergenic ATCCCCAGATACAATGGACAAT chr2:207682912–207683088 st2 12
21-1 Intron BC058547 TGTGATATCATGGTTCCTGGGA chr9:136881792–136881939 st2 2
39 LINE AGGGGACCAAAGAGATATATAG chr6:120378000–120378122 st+ 5
93 Intergenic CATCAGAATTCATGGAGGCTAGA chr3:48332858–48332955 st2 1
132 Intron OSBP2 CACCTTGCGCTACTCAGGTCTGC chr22:29457541–29457630 st+ 7
190 Intergenic TAGTCCCTTCCTTGAAGCGGTC chrX:149146896–149146977 st+ 4
244 Intron EDA-A2 CTGTCCTAAGGTTGTTGAGTT chrX:69159432–69159498 st+ 16
Novel microRNAs identified with high confidence, but no star sequence detected
3 Intergenic ACAGGAAAGAATAAGAAGTCAT chr17:20107032–20107214 st2 2
15-1 Intergenic TGGGGCGGAGCTTCCGGAG chr16:15156208–15156360 st2 6
15-2 Intergenic TGGGGCGGAGCTTCCGGAG chr16:2125979–2126131 st2 6
15-3 Intergenic TGGGGCGGAGCTTCCGGAG chr16:16311259–16311411 st+ 6
19 Intron CRYGN AGGTGCTCCAGGCTGGCTCACA chr7:150761508–150761658 st2 1
21-2 Intron BC058547 TGTGATATCATGGTTCCTGGGA chr9:136881157–136881228 st2 1
22 Intron PHC2 GATGAGGATGGATAGCAAGGAAG chr1:33570591–33570735 st2 16
35 Intergenic GAGCAATGTAGGTAGACTGTTT chr12:122586909–122587034 st+ 1
43 Intergenic TGTCCTCTAGGGCCTGCAGTCT chr22:34061633–34061751 st+ 5
46 CDH2 CGGGGAGAGAACGCAGTGACGT chr15:91248611–91248727 st+ 10
48 Intergenic AGCGCGGGCTGAGCGCTGCCAGTC chr5:92982149–92982263 st2 1
53-1 ROR2/LINE AAAGGCATAAAACCAAGACA chr9:93438354–93438464 st+ 14
53-2 LINE AAAGGCATAAAACCAAGACA chr9:93438367–93438448 st2 14
60 Intergenic TGTGTGGATCCTGGAGGAGGCA chr9:129492787–129492895 st2 2
70 Intergenic TAACGCATAATATGGACATGT chr5:170746265–170746369 st2 2
72 Intergenic TTCTCAAGAGGGAGGCAATCAT chrX:146139351–146139453 st2 4
75-1 Intergenic TTTGGGACTGATCTTGATGTCT chr12:68264769–68264870 st2 4
92-1 Intron WBSCR17 2 AAGGAACCAGAAAATGAGAAGT chr7:70410594–70410692 st2 1
92-2 Intron WBSCR17 + AAGGAACCAGAAAATGAGAAGT chr7:70410596–70410690 st+ 1
94 Intergenic TGAGGGACAGATGCCAGAAGCA chr2:69184307–69184404 st+ 3
99 Intron DMD TTGAGGAAAAGATGGTCTTATT chrX:32511694–32511790 st2 1
108 Intergenic CGGCGGGGACGGCGATTGGTC chr11:61339205–61339300 st2 1
111 Intergenic AGCTTTTGGGAATTCAGGTAG chr4:153629927–153630020 st2 4
113 Intergenic AAGAGGAAGAAATGGCTGGTTCTCAG chr1:245431892–245431985 st2 1
118 Intergenic AGGATTTCAGAAATACTGGTGT chr11:126363560–126363652 st2 3
120 Intergenic GCTCGGACTGAGCAGGTGGG chr1:26105440–26105532 st2 7
122 Intergenic ACAGGGCCGCAGATGGAGACT chr6:159105681–159105773 st2 1
127 Intergenic TTTGTATGGATATGTGTGTGTAT chr8:78041555–78041645 st2 1
135 Intron SCHIP1 GCAGAGAACAAAGGACTCAGT chr3:160483129–160483217 st+ 2
142-1 Intron RP11-529I10.4 + AAGGGCTTCCTCTCTGCAGGA chr10:103351160–103351248 st+ 23
142-2 Intron RP11-529I10.4 2 AAGGGCTTCCTCTCTGCAGGA chr10:103351160–103351248 st2 23
150 SINE GGCGACAAAACGAGACCCTGT chr6:155216181–155216267 st+ 7
158 Intergenic TGAGGAGATCGTCGAGGTTGG chr8:96154315–96154400 st2 1
159 Intron TRPC6 ACTGATTATCTTAACTCTCTGA chr11:100895761–100895846 st2 1
160 LINE TCTCTGAGTACCATATGCCTTGT chr3:101165848–101165932 st2 1
164 Intergenic AGAAGGGGTGAAATTTAAACGT chr16:14902866–14902949 st+ 4
167 Intergenic TCTGGCCTTGACTTGACTCTTT chr12:103509541–103509624 st+ 1
171 LTR AACTAGTAATGTTGGATTAGGG chr3:79639727–79639809 st+ 1
172 Intergenic TGCCTGGAACATAGTAGGGACT chr1:62317042–62317124 st2 8
189 Intergenic AGATGTATGGAATCTGTATAT chr14:27172246–27172327 st2 2
191 Intergenic ATATGTATATGTGACTGCTACT chr10:58734245–58734325 st2 1
Novel miRNA Discovery
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The discovery of miRNAs has revealed a previously unantic-
ipated layer of regulation that integrates the transcriptome (the
complete set of RNAs expressed in a cell) with the proteome
(complete set of proteins expressed). The ,700 miRNAs
uncovered from the human genome so far (as cataloged in
miRBase) are predicted to target and repress over 60% of the
protein coding genes [26]. Genome-wide miRNA predictions
estimate that the true number of miRNAs may be anywhere from
10–100 times more than the current numbers [11]. Indeed, large-
scale cloning and deep sequencing efforts in the last few years have
led to a doubling of the number of human miRNAs from ,470
(miRBase v8) to ,700 (miRBase v13) and the miRNA targeted
transcriptomes from .30% to .60% protein coding genes
[26,27], though the number of discovered miRNAs still falls short
of the upper predicted limits of tens of thousands.
We used Next Generation Sequencing (NGS) technology to
identify novel miRNAs in the female reproductive tract of women.
In addition to our 7 confirmed novel miRNAs, many of the 51
high confidence novel miRNAs could also be eventually
confirmed. The only feature that distinguishes a high confidence
novel miRNA from a confirmed miRNA by our criteria is
experimental evidence for both the miRNA and its star sequence
within the collection of NGS sequences from a given samples. The
novel miRNAs that we discovered occur generally in low
abundance (,1000 copies in 2–10 million sequences per
sequencing lane for a sample). It is therefore, highly likely that
deeper sequencing of the tissues we sampled or other new tissues
where they may occur in greater abundance may reveal a miRNA
star sequence for the majority of high confidence miRNAs in
which case they can be converted to confirmed status.
Previous deep sequencing efforts to identify novel miRNAs have
typically relied upon data from a single human sample
[14,16,17,23] while one recent study used tiling array data from
14 human cell lines [15]. To date, this study represents the largest
set of samples analyzed together by deep sequencing to identify
novel miRNAs. The large collection of tissue and cell line samples
used in this study allowed us to capture a large number of novel
miRNA candidates detectable in some samples but not others. In
fact, only one novel candidate (‘‘hsa-bcm-miR-265’’) was detected
in more than a third of the samples, with about 40% of the 141
putative miRNAs being detected in only a single sample.
Arguably, our approach has allowed us to uncover many more
novel miRNAs than what might be uncovered in a single sample.
For instance, the recent miRDeep study [14] uncovered 10 novel
miRNA candidates in the HeLa cell line, while we uncovered 104
potential candidates (seven confirmed, 51 high confidence, and 46
potential) across all of our 103 samples. The novel miRNAs that
we identified were typically low abundance as compared to most of
the known miRNAs, explaining how they might have eluded
previous efforts of detection.
Since sequencing is becoming faster, cheaper, and deeper, we
anticipate the number of miRNAs to possibly approach the
numbers estimated by some whole genome prediction algorithms.
If this happens, it is possible that the miRNA-regulated
transcriptomes include most of the genes in our genome, making
them widespread agents of gene silencing. From the data that we
have generated, it is clear that the most abundant miRNAs in
mammalian systems have likely been found. It is possible that the
lower abundance novel miRNAs uncovered here are present in
higher abundance in as yet unanalyzed tissues or cell types. It is
also possible that there are major miRNAs (i.e., the majority of
known miRNAs) that have a strong influence on gene silencing
and minor miRNAs (i.e., the majority of novel miRNAs) that have
a subtle effect on fine tuning gene expression. In any event, only
when the complete miRNAome is determined can we understand
the full impact of miRNAs on gene expression on a genome-wide
scale. Our novel miRNA detection study has added significantly to
the work to complete the miRNAome.
bcm-miR UCSC Blat Sequence Position (st=strand) Samples detected
192 Simple repeat ATCATGTATGATACTGCAAACA chr17:72597094–72597174 st+ 3
203 Intergenic ACAGTGAGGTAGAGGGAGTGC chr4:9689335–9689412 st2 5
204 Intron AK094607 CAGGCAGTGACTGTTCAGACGTC chr1:98283407–98283484 st2 17
210-1 Intron FASTKD2 + GCTGCACCGGAGACTGGGTAA chr2:207356202–207356278 st+ 14
210-2 Intron FASTKD2 2 GCTGCACCGGAGACTGGGTAA chr2:207356203–207356277 st2 14
212 Intergenic AAGAGAACTGAAAGTGGAGCCT chr6:36698191–36698267 st2 1
215 Intron COL5a2 GCAGTAGTGTAGAGATTGGTT chr2:189706007–189706082 st2 9
219 Intergenic TGTGTTAGAATAGGGGCAATAA chr9:18563304–18563377 st+ 1
223 Intergenic TGAGGATATGGCAGGGAAG chr2:134601163–134601236 st+ 1
226-1 Intron LONRF1 2 TGGCCAAAAAGCAGGCAGAGA chr8:12629112–12629184 st2 1
226-2 Intron LONRF1 + TGGCCAAAAAGCAGGCAGAGA chr8:12629117–12629179 st+ 1
230 Intergenic CAGGCGTCTGTCTACGTGGCTT chr17:77032732–77032802 st2 1
232 LTR CAGGTAGATATTTGATAGGCAT chr9:111313576–111313646 st2 2
245 Intergenic TTCGCGGGCGAAGGCAAAGTC chr1:247087199–247087265 st+ 5
261 Intron ACBD6 TAAATAGAGTAGGCAAAGGACA chr1:178674081–178674139 st2 4
262 ncRNA TGGGCTAAGGGAGATGATTGGGT chrX:153650065–153650123 st+ 26
265 Intergenic GGAGGAACCTTGGAGCTTCGGC chr22:29886048–29886105 st2 49
268 SINE GAGGCTGATGTGAGTAGACCACT chr18:31768049–31768103 st2 3
doi:10.1371/journal.pone.0009637.t002
Table 2. Cont.
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Ethics Statement
Patients undergoing elective gynecologic surgery at Ben Taub
General Hospital or St. Luke’s Episcopal Hospital were
approached prior to surgery for participation. After written
informed consent, patients underwent scheduled surgical proce-
dures. All tissues collected for this study were collected under
Baylor College of Medicine Institutional Review Board (IRB)
approval and IRB approval from each individual hospital.
Figure 2. Predicted secondary structures of the precursor hairpins for the seven confirmed novel miRNAs. Mfe, predicted mean free
energy level of the hairpin. Mature miRNA and miRNA star sequences—both detected by deep sequencing—are denoted (red and blue, respectively),
as well as predicted Drosha cut points (red arrows). Asterisks indicate the small 39 overhangs which are known to be typical for microRNAs.
doi:10.1371/journal.pone.0009637.g002
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RNA was extracted from tissues or cell lines using the mirVana
miRNA Isolation Kit (Ambion, Austin, TX) per manufacturer’s
instructions for total RNA isolation. RNA quality and the presence
of small RNAs were inspected on a 2100 Bioanalyzer (Agilent).
After strict RNA quality was assured, 15 mg of total RNA was used
for small RNA library creation using Illumina’s DGE small RNA
sample prep kit per manufacturer’s instructions. Purified cDNA
was quantified with the Quant-iT PicoGreen dsDNA Kit
(Invitrogen) and diluted to 3 pM for sequencing on the Illumina
1G Genome Analyzer (Solexa)(University of Houston). Each
library was sequenced in a single lane.
Small RNA Mapping
Sequence reads with Solexa 39 adapter (the read length being
36 nt) were picked for miRNA mapping (the same adaptor being
used for each sequencing run). Each sequence read was passed
through a number of quality control filters. Reads which did not
pass the Illumina chastity and no-calls filter were removed. Reads
with copy number less than 4, length less than 10 nt, or more than
Figure 3. Relative abundance levels of novel miRNAs across samples. (A) Total number of sequence reads (summed across all samples) for
both known miRNAs (404 in all) and novel miRNAs (note the log base 10 scale). High confidence, novel miRNA was found to form part of a miRNA-like
hairpin, yet the hairpin star sequence was not detected by the deep sequencing (51 in all); Confirmed, novel miRNA formed part of a miRNA-like
hairpin, with the star sequence also being detected (seven in all). (B) Heat map representing the number of sequence reads mapping to each novel
miRNA hairpin across the samples. (C) Detection of hsa-bcm-miR-15 by qPCR. RQ, Relative Quantification (HEK293 sample as reference). hsa-bcm-miR-
15 was detected at ,300 sequence reads in OVTOKO cells and ,100 reads in HEK293.
doi:10.1371/journal.pone.0009637.g003
Novel miRNA Discovery
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matching the E. coli genome were removed using WU BLAST
[28]. The remaining reads (which we termed ‘‘valid’’ sequence
reads) were compared with known mature miRNA hairpins
(miRBase 13.0) [29]. Reads were mapped as either exact match or
loose match (loose match only for reads without an exact match).
For loose match (which would account for miRNAs being
subjected to non-templated nucleotide changes and RNA editing
[24]), up to three mismatches were allowed in a single alignment
(by our experience, allowing four mismatches yielded diminishing
returns decreasing the cost benefit of engaging all sequence reads
that pertain to a specific miRNA versus the increase in alignment
times); for loose matches, we used a custom Smith-Waterman local
alignment algorithm, where our gap penalty was 23, match score
was 2, and mismatch penalty was 21, with a cutoff of 1.46. The
reads that did not align to any known miRNA were passed to our
novel miRNA discovery platform as described below.
Novel miRNA Discovery
Our basic approach for novel miRNA discovery has been
described previously [13]. Briefly, each sequence which passed our
quality control filters was first mapped on the reference genome
sequence (hg18) plus 200 bases of flanking the sequence on either
side were extracted to find the putative hairpin. This extracted
sequence was then folded using RNAfold of the Vienna RNA
folding package [22], in order to determine secondary RNA
structure. After folding of the long (,425 nt) sequence (and
confirmation that it contains a miRNA-like hairpin with the
sequenced tag in the proper place) the putative precursor sequence
was trimmed down to include only the hairpin bases (60–150 nt)
and refolded to confirm that the structure is maintained in both
the larger and shorter contexts. To determine if a structure forms a
plausible miRNA hairpin, we applied the three Ambros criteria
[20]: 1) the mature putative miRNA sequence must rest on one
side of a single hairpin; 2) the putative miRNA sequence must bind
relatively tightly (i.e. at least 16 bound bases in the first 22 or fewer
bases of the miRNA) within the hairpin stem containing no large
or energetically unfavorable loops (i.e. a single loop with more
than 6 bases in the arm of the hairpin); and 3) the putative hairpin
must have a miRNA-appropriate energy (free energy below
225 kcal/mol). We recognized small RNA sequences as repre-
senting putative novel miRNA if all the above were met.
We carefully curated the set of putative novel miRNAs and
divided them into four different categories: ‘‘not likely,’’
‘‘potential,’’ ‘‘high confidence,’’ and ‘‘confirmed.’’ Candidates
were flagged as ‘‘not likely’’ if any of the following was determined:
the mature sequence did not map clearly within a specific region of
15–25 nt of the predicted hairpin (e.g. were scattered evenly across
the full length of the hairpin), or fell within the hairpin loop, or
mapped to known tRNAs or rRNAs. (Though the minimum
length of a miRNA is thought to be 17 nt, we used a lower limit of
15 for the mapping region, to account for the fact that microRNAs
exhibit significant length heterogeneity at the 39 end and to
capture all isomiRNAs [23,24].) Candidates were categorized as
‘‘high confidence’’ if they passed all of the above criteria, and in
addition formed a hairpin with predicted Drosha and Dicer cut
sites that were able to yield a mature miRNA sequence matching
the actual miRNA sequence read, as well as not mapping to
known snoRNAs or snRNAs. Candidates were categorized as
‘‘potential’’ if they had weak predicted processing sites in the
hairpin, yet the hairpin showed a stable 59 end (candidates
representing snoRNAs and snRNAs that otherwise fulfilled the
‘‘high confidence’’ criteria were also categorized as ‘‘potential’’).
Candidates were categorized as ‘‘confirmed’’ if they met all of the
criteria of the ‘‘high confidence’’ candidates, and in addition to
both having a predicted star sequence that was detected in our
deep sequencing pool and forming a hairpin with a stable 59 end
and a variable 39 end.
Reverse Transcription (RT) of Mature MicroRNA from
Total RNA
Total RNA isolated from OVTOKO and HEK293 cell lines
was reverse transcribed using the TaqManH MicroRNA Reverse
Transcription Kit from Applied Biosystems (Part Number
4366596) following the manufacturers suggested protocol and
specific RT stem-loop primers for mature novel_hsa-bcm-miR-15
sequence and for U6 for an internal control.
qPCR of cDNA Products
PCR products were amplified from each cDNA sample using
the TaqMan MicroRNA Assay together with the TaqManH
Universal PCR Master Mix. Following the manufacturer’s
recommended reaction conditions, using the Applied Biosystems
Veriti system. After 40 cycles of the recommended cycle
conditions, data was collected from the machine and analyzed
using the Applied Biosystem qPCR software. Using the compar-
ative ggCT method, we used the HEK293 as the reference
sample for OVTOKO levels of expression and small RNA U6 as
the endogenous control to normalize the expression levels of the
novel_ hsa-bcm-miR-15 target.
Supporting Information
Supporting Data File S1 The set of 132 putative novel
miRNAs with sequence copy counts for each sample.
Found at: doi:10.1371/journal.pone.0009637.s001 (0.17 MB
XLS)
Supporting Data File S2 The predicted set of RNA hairpin
secondary structures for the 132 putative novel miRNAs.
Found at: doi:10.1371/journal.pone.0009637.s002 (2.74 MB
XLS)
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